A series of studies were undertaken by the Childrens Cancer Study Group between 1968 and 1972 to evaluate the optimum schedule and dosage of L-asparaginase as a single agent in induction and maintenance of children with previously treated acute lymphocytic leukemia. Six different dosages of enzyme were administered (3600-840,000 IU/4 wk/m2). The optimal dose of L-asparaginase was found to be 12,000 IU/m2 given three times per week for a total dose of 144,000 IU/m2. Sixty-three percent of children treated with this dosage achieved a bone marrow remission. The intramuscular method of administration is as effective and produced less significant sensitivity reactions than the intravenous method. Reinduction, after an unmaintained remission, with L-asparaginase was possible in 32% of the cases. L-Asparaginase used as a maintenance agent did not result in a significant increase in remission duration when compared to no maintenance therapy. However, patients who received L-asparaginase maintenance had a median remission duration of 66 days as compared to 41 days for the no-maintenance group.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Impact of single-nucleotide variants and individual characteristics on adverse events of L-asparaginase in children with acute lymphoblastic leukemia.
Front Pharmacol
October 2024
Faculty of Medicine and Psychology, Autonomous University of Baja California, Tijuana, Mexico.
Introduction: L-Asparaginase (L-Asp) is a key drug in the treatment of acute lymphoblastic leukemia (ALL); however, it is commonly associated with the occurrence of adverse events (AE). Risk factors such as age, sex, nutritional status, and some single nucleotide variants (SNVs) in specific genes could be related to hypersensitivity reactions to L-Asp. The objective of this study was to identify the influence of individual characteristics and three SNVs in the and genes on the occurrence of the most significant adverse events caused by the use of L-Asp in Mexican children with ALL.
View Article and Find Full Text PDFOptimizing the combination of chemotherapeutic drugs along with radiotherapy for extranodal NK/T-cell lymphoma.
Ther Adv Med Oncol
October 2024
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Road, Chaoyang District, Beijing 100021, China.
Background: Extranodal natural killer/T-cell lymphoma (ENKTCL) has a unique treatment principle. However, the optimal combination of drugs along with radiotherapy (RT) is unknown.
Design: Retrospective cohort study.
[Molecular profiling of myeloid/natural killer (NK) cell precursor acute leukemia].
Rinsho Ketsueki
October 2024
Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU).
Article Synopsis
- Myeloid/natural killer (NK) cell precursor acute leukemia (MNKPL) is proposed as a unique leukemia type but lacks international consensus due to its rarity and unclear molecular features.
- Multi-omics analysis shows that MNKPL is different from other types of leukemia and reveals specific genetic markers, such as NOTCH1 and RUNX3 activation, along with BCL11B downregulation.
- A case study indicates poor patient outcomes even after treatment, but MNKPL cells are sensitive to the drug L-asparaginase, potentially improving treatment options.
Insights into Asparaginase Allergic Responses: Exploring Pharmacogenetic Influences.
Pharmaceutics
August 2024
Post Graduate Program in Child and Adolescent Health, Universidade Federal do Rio Grande do Sul, Porto Alegre 90035-003, RS, Brazil.
Acute lymphoblastic leukemia represents the most prevalent childhood cancer. Modern chemotherapy has significantly improved outcomes, achieving EFS rates of 80% and OS rates nearing 90% in developed nations, while in developing regions, rates remain below 50%, highlighting disparities, and this difference is due to several factors. Genetic variability plays a role in these drug response disparities, presenting single-nucleotide variations (SNVs).
View Article and Find Full Text PDFModified SMILE (mSMILE) is active in the treatment of pediatric Epstein-Barr virus-associated natural killer/T-cell lymphoma: a single center experience, case series.
Transl Pediatr
July 2024
Department of Hematology and Oncology, Children's Hospital of Nanjing Medical University, Nanjing, China.
Background: The Epstein-Barr virus-associated natural killer (NK) and T-cell lymphoma (EBV + NK/T cell lymphoma) is a severe illness mainly affecting children and young adults, often resulting in a poor prognosis. To date, there is no consensus on an established treatment strategy. This study aims to evaluate the efficacy and safety of the mSMILE (modified steroid, methotrexate, ifosfamide, L-asparaginase, and etoposide) chemotherapy regimen in treating EBV+ NK/T-cell lymphoma and to provide insights into potential treatment outcomes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!